Emerging Markets Report: Meeting the Moment

Vinergy Capital Evolving to MedBright AI Investments with Name Change

An Emerging Markets Sponsored Commentary

ORLANDO, Fla., Nov. 21, 2023 (GLOBE NEWSWIRE) -- In previous issues of the Emerging Markets Report, we’ve covered what we believe will be transformative for the Issuer discussed below via the adoption of Artificial Intelligence in Health Care. It’s clear to us that AI driven Health Care will be smarter, more effective and more compassionate as it provides better health care outcomes to more and more patients.

And so it makes sense for MedBright AI Investments Inc. (OTCQB: MBAIF, CSE: MBAI) (the "Company" or "MedBright AI") formally known as Vinergy Capital Inc. to align its brand with this opportunity, all while developing and refining a portfolio of A.I. health care technologies and acquiring more consultants and human capital under its proverbial roof. Consistent with this plan, the Company decided that a name change to MedBright AI Investments is in order, which is trading under the ticker “MBAIF” on the OTCQB, and is the new name and ticker for the Company formerly known as Vinergy Capital.

As we see it, the Company has gone through an evolution over the past few months, rapidly expanding and improving in the race to seize market share in the highly lucrative Health Care/A.I. opportunity. The name change to MedBright AI reflects the Company’s current business purposes and more accurately identifies its brand.

The foray into A.I. driven health care is well-founded. As we previously reported a recent research report by a firm completely unrelated to Vinergy projects that the “Worldwide Artificial Intelligence in Healthcare Market Size is expected to reach USD 280.77 Billion by 2032.” (source link.)

Since we last published that report MedBright AI (formally Vinergy Capital) has been busy.

In October, the Company announced that it had added another A.I. expert to its investment committee, with Trevor Vieweg, a co-founder of Limmi, an AI platform focused on powering the world's most complex healthcare data analytics systems. Vieweg has an outstanding resume including an important stint as Head of Product Development for a big NASDAQ outfit.

When we see hires like this, they can be a big deal, as the hiring very likely brings the new team member’s contacts and relationships as well as their expertise. And of course, when an industry pro jumps into a deal it generally sends a signal that a better mind than the layman saw something and wants to be involved.

On top of this was a powerful announcement that the Company had made another significant investment in the aforementioned Limmi, a FDA and HIPPA compliant Artificial Intelligence Platform.

Limmi’s tech is described as “a cutting-edge data and analysis artificial intelligence platform for life sciences applications that is both FDA and HIPAA compliant. Through machine learning models, Limmi transforms life science data into actionable insights to transform drug discovery and early disease detection.”

Read that last line one more time… “Limmi transforms life science data into actionable insights to transform drug discovery and early disease detection.”

Health Care Artificial Intelligence. Transforming Drug Discovery. Identifying diseases earlier.

The future for A.I. in improving patient outcomes is compelling.

Probably just about the right time to have a name that meets the moment.

About The Emerging Markets Report:

The Emerging Markets Report is owned and operated by Emerging Markets Consulting (EMC), a syndicate of investor relations consultants representing decades of experience. Our network consists of stockbrokers, investment bankers, fund managers, and institutions that actively seek opportunities in the micro and small-cap equity markets.

For more informative reports such as this, please sign up at:

Must Read OTC Markets/SEC policy on stock promotion and investor protection

Section 17(b) of the Securities Act of 1933 requires that any person that uses the mails to publish, give publicity to, or circulate any publication or communication that describes a security in return for consideration received or to be received directly or indirectly from an issuer, underwriter, or dealer, must fully disclose the type of consideration (i.e. cash, free trading stock, restricted stock, stock options, stock warrants) and the specific amount of the consideration. In connection therewith, EMC has received the following compensation and/or has an agreement to receive in the future certain compensation, as described below.

EMC has been paid $90,000 by MedBright AI Investments Inc. EMC does not independently verify any of the content linked-to from this editorial. | Please read our full disclaimer.

Emerging Markets Consulting, LLC
Florida Office
390 N Orange Ave. Suite 2300
Orlando, FL 32801

Primary Logo

NOTE: This content is not written by or endorsed by "WXIN", its advertisers, or Nexstar Media Inc.

For inquiries or corrections to Press Releases, please reach out to GlobeNewswire.